I-Mab
NASDAQ:IMAB

  • LAST PRICE
    1.6000
  • TODAY'S CHANGE (%)
    0.1000 (6.6667%)
  • Bid / Lots
    1.5600/ 3
  • Ask / Lots
    1.6000/ 57
  • Open / Previous Close
    1.5000 / 1.5000
  • Day Range
    1.5000
    1.6100
  • 52 Week Range
    1.1600
    3.1700
  • Volume
    153,189

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Jun 6, 2024

      Show headlines and story abstract

    • 7:01AM ET on Thursday Jun 06, 2024 by PR Newswire
      Companies Mentioned: IMAB

      I-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced the appointment of Dr. Phillip Dennis as Chief Medical Officer. Dr. Dennis, who will join I-Mab effective June 17, 2024, will lead the Company's global clinical development efforts and serve as a member of I-Mab's Executive Leadership Team.

    • 7:00AM ET on Thursday Jun 06, 2024 by Dow Jones
      Companies Mentioned: SNY, AZN, IMAB

      I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer

      PR Newswire

      ROCKVILLE, Md., June 6, 2024

      ROCKVILLE, Md., June 6, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced the appointment of Dr. Phillip Dennis as Chief Medical Officer. Dr. Dennis, who will join I-Mab effective June 17, 2024, will lead the Company's global clinical development efforts and serve as a member of I-Mab's Executive Leadership Team.

    • 7:00AM ET on Thursday Jun 06, 2024 by Dow Jones
      Companies Mentioned: SNY, AZN, IMAB

      I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer

      PR Newswire

      ROCKVILLE, Md., June 6, 2024

      ROCKVILLE, Md., June 6, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced the appointment of Dr. Phillip Dennis as Chief Medical Officer. Dr. Dennis, who will join I-Mab effective June 17, 2024, will lead the Company's global clinical development efforts and serve as a member of I-Mab's Executive Leadership Team.

Peers Headlines